Skip to content

X1 Biotech

1 viewer · 30d

Total raised

$40K

+$40K this year

1 filing since 2026 · latest SAFE filed

Cumulative raised
LAST ROUND
SAFE · $40K
ROUNDS
1
INVESTORS
2
FOUNDED
N/A
HQ
Needham, MA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
1

AI overview

Updated

X1 Biotech Inc. is a Needham, Massachusetts preclinical biotechnology company developing small-molecule therapeutics for vascular repair. Its approach modulates a shared upstream regulatory pathway implicated in vascular degeneration and fibrotic disease, with preclinical activity reported across inherited small-vessel disease, pulmonary fibrosis, aberrant angiogenesis in eye disease, and neurodegenerative conditions. The company runs a deliberately narrow pipeline focused on a single lead asset, X101, and was co-founded by Harvard Medical School-affiliated ophthalmology and vascular biology researchers.

What sets it apart

Targets a single shared upstream regulator (RUNX1) driving vascular degeneration and fibrosis, using a repurposed small molecule with existing human safety history to reach the clinic faster and more cheaply than a de novo program.

Funding history

1 round
SAFE+1May 20, 2026
Form D
+$40K$40K total

Latest SEC filings

via EDGAR · CIK 0002068848
Form D · May 20, 2026NewView on EDGAR

Products

1 tracked

X101

Preclinical small-molecule therapeutic

A repurposed small-molecule RUNX1 inhibitor (Ro24-7429) being developed first for CADASIL, an inherited cerebral small-vessel disease, with expansion planned into other vascular-degeneration and fibrotic indications.

  • Small-molecule RUNX1 inhibitor targeting a shared upstream driver of vascular and fibrotic disease
  • Repurposed compound (Ro24-7429) with prior human exposure, supporting a capital-efficient path
  • CADASIL-first development strategy with expansion potential into idiopathic pulmonary fibrosis
  • Preclinical activity reported across small-vessel disease, fibrosis, aberrant angiogenesis and neurodegeneration

Links

WebsiteSEC EDGAR filings